Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 14:13 (1357 d 18:39 ago) – Posting: # 22227
Views: 3,613

Dears
Also Regarding AUC widening, is it applicable in both partially and fully replicate designs or fully replicate design only as FDA referred to the published book chapter for RSABE for AUC and Cmax in fda draft guidance for progesterone? So could we apply it in general or it’s not applicable?

Complete thread:

UA Flag
Activity
 Admin contact
23,297 posts in 4,892 threads, 1,686 registered users;
64 visitors (0 registered, 64 guests [including 9 identified bots]).
Forum time: 08:53 CET (Europe/Vienna)

Laws are like sausages – it is better
not to see them being made.    Otto von Bismarck

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5